Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia

John B Christoforidis, Daniel J. DeAngelo, Donald J. D'Amico

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PURPOSE: To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). DESIGN: Interventional case report. METHODS: A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. RESULTS: The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. CONCLUSIONS: Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.

Original languageEnglish (US)
Pages (from-to)398-400
Number of pages3
JournalAmerican Journal of Ophthalmology
Volume135
Issue number3
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Chronic Phase
Retinal Hemorrhage
Therapeutics
Hemorrhage
Imatinib Mesylate

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia. / Christoforidis, John B; DeAngelo, Daniel J.; D'Amico, Donald J.

In: American Journal of Ophthalmology, Vol. 135, No. 3, 01.03.2003, p. 398-400.

Research output: Contribution to journalArticle

@article{5212ad8ae7e64b5f9c0f728cf01fb26b,
title = "Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia",
abstract = "PURPOSE: To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). DESIGN: Interventional case report. METHODS: A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. RESULTS: The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. CONCLUSIONS: Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.",
author = "Christoforidis, {John B} and DeAngelo, {Daniel J.} and D'Amico, {Donald J.}",
year = "2003",
month = "3",
day = "1",
doi = "10.1016/S0002-9394(02)01964-5",
language = "English (US)",
volume = "135",
pages = "398--400",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia

AU - Christoforidis, John B

AU - DeAngelo, Daniel J.

AU - D'Amico, Donald J.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - PURPOSE: To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). DESIGN: Interventional case report. METHODS: A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. RESULTS: The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. CONCLUSIONS: Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.

AB - PURPOSE: To report a case of leukemic retinopathy before and after treatment with imatinib mesylate (formerly STI-571) for chronic myelogenous leukemia (CML). DESIGN: Interventional case report. METHODS: A 58-year-old man diagnosed with stable phase CML (SP-CML) presented with blurry vision. Fundoscopy revealed several flame-shaped hemorrhages in the macular region in both eyes. One month after this initial visit, imatinib therapy was initiated. RESULTS: The patient noticed improvement in his visual as well as his medical symptoms; on repeat examination 6 months after the initial visit, the retinal hemorrhages had resolved and remained so after 18 months. CONCLUSIONS: Imatinib appears to be an effective treatment for SP-CML, and the improvement in visual and medical symptoms in our case report correlates with this.

UR - http://www.scopus.com/inward/record.url?scp=0344089315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344089315&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(02)01964-5

DO - 10.1016/S0002-9394(02)01964-5

M3 - Article

C2 - 12614767

AN - SCOPUS:0344089315

VL - 135

SP - 398

EP - 400

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -